KLOW Protocol

KLOW is a research peptide combination that builds upon the GLOW protocol by adding KPV for enhanced anti-inflammatory effects. This 80mg blend typically contains 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual components have varying levels of research support, no clinical trials have examined this specific four-peptide combination. The protocol remains investigational with theoretical benefits based on complementary mechanisms.

• Multi-Modal Healing
• Enhanced Tolerability
• Convenience Factor

Theoretical synergistic effects from four peptides - tissue repair, anti-inflammation, cellular regeneration

Each peptide contributes different mechanisms: GHK-Cu modulates genes, TB-500 enhances cell migration, BPC-157 upregulates growth factors, KPV inhibits NF-κB

Research protocols from published literature — not dosing recommendations.

• GLOW Protocol — Use Caution: KLOW already contains all GLOW components plus KPV - combining would result in double dosing of base peptides
• Ipamorelin — Unknown: No studies on combination - theoretical compatibility based on different mechanisms
• NAD+ — Unknown: No data on combining KLOW with NAD+ - both affect cellular processes through different pathways
• Anticoagulants — Use Caution: Components may affect wound healing and clotting - medical supervision required
• Growth Hormone — Avoid Combination: Multiple components affect GH pathways - risk of excessive stimulation
• Immunosuppressants — Use Caution: Components may interfere with immunosuppressive therapy - consult physician

Supplies:

• KLOW 80mg vial (pre-mixed blend)
• Bacteriostatic water (2-5mL)
• Insulin syringes
• Alcohol prep pads

1. 1Clean vial top with alcohol pad
2. 2Add 2-5mL bacteriostatic water (4mL creates 20mg/mL)
3. 3Gently swirl - do not shake
4. 4Solution should be clear to slightly cloudy
5. 5Label with date and concentration
6. 6Store in refrigerator immediately
7. 7Use within 4-6 weeks

Individual responses vary widely with no predictable timeline. Some users report reduced inflammation within days. Wound healing effects may take 2-4 weeks if they occur. No clinical data exists to set realistic expectations. Placebo effects may contribute to perceived benefits.

No safety studies on four-peptide combination. Individual peptides generally well-tolerated in research. Injection site reactions common even with KPV. Long-term effects completely unknown. FDA has not approved any component for therapeutic use. Quality and contamination risks in unregulated market.

No safety studies on four-peptide combination. Individual peptides generally well-tolerated in research. Injection site reactions common even with KPV. Long-term effects completely unknown. FDA has not approved any component for therapeutic use. Quality and contamination risks in unregulated market.